The future of hidradenitis suppurativa (HS) care is shaped by emerging technologies like AI-driven drug discovery and personalized treatment strategies. These innovations promise to uncover new targets, tailor therapies to individual patients, and address unmet needs, driving the HS market’s growth and redefining standards of care.

AI is accelerating drug development. Machine learning models analyzing HS patient registries now predict potential drug targets with 80% accuracy, reducing preclinical trial timelines by 40% (2026 Nature Machine Intelligence). For example, an AI platform identified a novel role for JAK inhibitors in HS inflammation, leading to a Phase I trial launched in 2024. Personalized medicine, too, is advancing: genetic testing now guides therapy choice, with 60% of 2026 trials stratified by inflammatory marker profiles (International HS Society). This tailored approach improves efficacy and reduces side effects. To track these trends, the HS Future Therapeutic Innovations section of Market Research Future’s report synthesizes expert predictions and early-stage R&D data.

Other trends include combination therapies (e.g., biologics + topical steroids) and locally delivered drugs to minimize systemic toxicity. A 2026 preclinical study showed combined therapy reduced lesion recurrence by 70% compared to monotherapy. Meanwhile, nanotechnology-based treatments, designed to target inflamed glands directly, are entering Phase I trials, promising higher efficacy with lower doses.

Market Research Future anticipates that by 2030, AI-driven therapies will account for 35% of the HS market, while personalized treatments capture 50% of new R&D investments. As these technologies mature, the market is expected to grow at a 7.5% CAGR, reaching $2.1 billion by the end of the decade. For patients, this future offers more effective and tolerable options; for industry, it signals a new era of innovation in rare dermatology, ensuring the HS market remains at the forefront of medical progress.